2 completed, 2 recruiting, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Sickling Disorder Due to Hemoglobin S: new trials by email Literature Review of Sickling Disorder Due to Hemoglobin S trials Research Report on Sickling Disorder Due to Hemoglobin S
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) 131I-apamistmab, Sirolimus, Campath - Sickling Disorder Due to Hemoglobin S | Phase 1 | Recruiting | Columbia University | 24 | 2025-04-28 | 2026-06-10 |
| A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation, Matched sibling donor transplantation - HbS Disease, Hemoglobin S Disease | Phase 2 | Recruiting | University of Regensburg | 212 | 2021-06-30 | 2024-05-13 |
| Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell Rapid manual partial exchange transfusion, Simple Transfusion - Anemia, Sickle Cell, Sickling Disorder Due to Hemoglobin S | Completed | Chattanooga-Hamilton County Hospital Authority | 9 | 2015-09-01 | 2018-07-27 | |
| Effects of HQK-1001 in Patients With Sickle Cell Disease HQK-1001, Placebo - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Terminated | HemaQuest Pharmaceuticals Inc. | 77 | 2012-07-01 | 2015-03-18 |
| A Study of HQK-1001 in Patients With Sickle Cell Disease HQK-1001 - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Completed | HemaQuest Pharmaceuticals Inc. | 52 | 2011-04-01 | 2013-06-19 |
Anemia, Sickle Cell (5) · Anemia (1) · Disease (1) · Sickle Cell Trait (1)
Anemia, Hemolytic (5) · Anemia, Hemolytic, Congenital (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Hemoglobinopathies (5) · Anemia (4) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
2,2-dimethylbutyric acid (2) · Alemtuzumab (1) · Exchange Transfusion, Whole Blood (1) · Iodine (1) · Sirolimus (1) · Whole-Body Irradiation (1)
HemaQuest Pharmaceuticals Inc. (2) · Chattanooga-Hamilton County Hospital Authority (1) · Columbia University (1) · University of Regensburg (1)
United States (4) · Canada (2) · Egypt (2) · Jamaica (2) · Lebanon (2) · Austria (1) · Germany (1)
Richard Ghalie, MD, MBA (2) · Jennifer Keates, MD (1) · Markus Y Mapara, MD (1) · Selim Corbacioglu, MD (1)